These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 2674990)

  • 1. Weekly epirubicin in patients with hormone refractory prostatic cancer--a two-year follow-up.
    Burk K; Schultze-Seemann W; Jonas D; Rodeck G
    Prog Clin Biol Res; 1989; 303():277-85. PubMed ID: 2674990
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly chemotherapeutic regimen in metastatic prostate cancer.
    Burk K
    Prog Clin Biol Res; 1989; 303():261-75. PubMed ID: 2674989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.
    Petrioli R; Rossi S; Caniggia M; Pozzessere D; Messinese S; Sabatino M; Marsili S; Correale P; Salvestrini F; Manganelli A; Francini G
    Urology; 2004 Feb; 63(2):321-6. PubMed ID: 14972482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prospective randomized multicenter phase III study of treatment of hormone refractory prostatic cancer: mitomycin C vs. 4-epirubicin vs. estramustine phosphate].
    Weissbach L
    Urologe A; 1992 Jan; 31(1):62. PubMed ID: 1553805
    [No Abstract]   [Full Text] [Related]  

  • 7. SMS 201-995 in the treatment of refractory prostatic carcinoma.
    Logothetis CJ; Hossan EA; Smith TL
    Anticancer Res; 1994; 14(6B):2731-4. PubMed ID: 7872709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
    Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
    Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.
    Petrioli R; Fiaschi AI; Francini E; Pascucci A; Francini G
    Cancer Treat Rev; 2008 Dec; 34(8):710-8. PubMed ID: 18620815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder.
    Canda AE; Tuzel E; Mungan MU; Yorukoglu K; Kirkali Z
    Eur Urol; 2004 Apr; 45(4):465-9; discussion 469-70. PubMed ID: 15041110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group].
    Taue R; Kanayama H; Kagawa S
    Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer.
    Gandhok NK; Looney S; Koochekpour S; Sartor O
    Urol Oncol; 2005; 23(3):163-7. PubMed ID: 15907715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?
    Ward JF
    Nat Clin Pract Urol; 2006 Jun; 3(6):310-1. PubMed ID: 16763642
    [No Abstract]   [Full Text] [Related]  

  • 14. Changes in tissue prostatic acidic phosphatase during endocrine treatment of patients with prostatic carcinoma.
    Grande M; Carlström K; Lundh-Rozell B; Stege R; Pousette A
    Scand J Urol Nephrol; 2005; 39(5):393-8. PubMed ID: 16257841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of 21-day continuous infusion of epirubicin in hormone-refractory prostate cancer patients.
    Berruti A; Mosca A; Bitossi R; Gorzegno G; Guercio S; Poggio M; Tampellini M; Porpiglia F; Ostellino O; Scarpa RM; Dogliotti L
    Anticancer Res; 2005; 25(6C):4475-9. PubMed ID: 16334129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Macrophage colony-stimulating factor for treatment of prostatic cancer with bone metastases].
    Hayashi T; Kakehi R
    Hinyokika Kiyo; 1993 Jan; 39(1):101-5. PubMed ID: 8460579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer.
    Francini G; Paolelli L; Francini E; Pascucci A; Manganelli A; Salvestrini F; Petrioli R
    Eur J Surg Oncol; 2008 Feb; 34(2):216-21. PubMed ID: 17502132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.
    Berruti A; Fara E; Tucci M; Tarabuzzi R; Mosca A; Terrone C; Gorzegno G; Fasolis G; Tampellini M; Porpiglia F; De Stefanis M; Fontana D; Bertetto O; Dogliotti L;
    Urol Oncol; 2005; 23(1):1-7. PubMed ID: 15885575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly epidoxorubicin therapy in hormone-refractory metastatic prostate cancer.
    Neri B; Barbagli G; Bellesi P; Di Loro R; Lombardi V; Lombardo C; Magrini T; Mottola A; Nicita G; Palminteri E; Ponchietti R; Raugei A; Intini C
    Anticancer Res; 1997; 17(5B):3817-20. PubMed ID: 9427786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study of the hormone-refractory prostate cancer clinical practice in an anti-cancer center].
    Zufferey L; Roques B; Fléchon A; Droz JP
    Bull Cancer; 2001 Dec; 88(12):1213-21. PubMed ID: 11792613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.